New exiting developments pioneered by Micreos include the world’s first targeted antibacterial products, set to replace antibiotics. The company is viewed as global leader spearheading this exciting new field. With Micreos endolysin technology, for the first time we can kill only the unwanted bacteria – including antibiotic resistant strains – while leaving the beneficial bacteria intact. Endolysins are phage derived enzymes introducing a new 2.0 era for phage therapy. Research shows that the use of endolysins does not induce resistance. This unlocks a completely new approach in dealing with the bacteria around us – also enabling daily use as long as needed while preserving the important biodiversity on our skin and in our gut.
Micreos‘ Staphefekt SA.100 is such an enzyme (endolysin), which kills only Staphylococcus aureus, including MRSA. It is also suitable for routine maintenance therapy, for inflammatory skin conditions such as eczema, rosacea, psoriasis and inflammatory acne.